Cozen O’Connor: Reichenberg, David

David Reichenberg

Member

New York

(212) 883-4956

(212) 986-0604

Recent News:

What it all boils down to in FTC vs. Qualcomm

David Reichenberg discussed the recent antitrust trial attacking Qualcomm’s business model with Mike Freeman of The San Diego Union-Tribune.

David’s work encompasses all aspects of the antitrust practice, including litigation, counseling, and mergers and acquisitions. He has successfully represented many major technology companies in high profile cases on the plaintiff and defense sides, such as successful litigation on behalf of Netflix in a class action in the Northern District of California, as well as on behalf of Arista Networks in a monopolization case against Cisco Systems involving the intersection of intellectual property and antitrust. He regularly advises Fortune 500 clients on the antitrust implications of potential business initiatives and has counseled and litigated on behalf of clients regarding all forms of unfair competition law. David has coordinated responses to investigations by the U.S. Department of Justice and Federal Trade Commission (on both the offensive and defensive sides). David is active in the ABA Antitrust Section, currently serving as a vice chair on the Trial Practice Committee. David started his career at a leading antitrust boutique, focusing on merger clearance and litigation, which included the successful resolution of a CID in federal court.

David has an active pro bono practice and, most recently, was the first-chair on a trial team that secured a favorable jury verdict in the Eastern District of New York on a 1983 civil rights claim under the Fourth Amendment. Previously, he was appointed by the Second Circuit Court of Appeals to represent a prisoner in a 1983 case and was successful in persuading the Second Circuit to reverse and vacate the lower court’s grant of summary judgment on three of the claims.

David earned his undergraduate degree, with honors and distinction, from Cornell University. David earned his law degree from Fordham University School of Law, where he was the ADR editor of the Urban Law Journal, member of the Moot Court Board and received the top grade in EU Competition Law.  

Experience

News

What it all boils down to in FTC vs. Qualcomm

February 10, 2019

David Reichenberg discussed the recent antitrust trial attacking Qualcomm’s business model with Mike Freeman of The San Diego Union-Tribune.

Why the FTC Thinks You Pay Too Much for Smartphones

January 12, 2019

David Reichenberg, a member in the firm's Antitrust Practice Group, was quoted in F3News' article "Why the FTC Thinks You Pay Too Much for Smartphones."

California Cases To Watch In 2019

January 01, 2019

David Reichenberg, a member in the firm's Commercial Litigation Department, was quoted in Law360's article, "California Cases To Watch In 2019."

FTC antitrust case against Qualcomm puts business model under microscope

December 30, 2018

David Reichenberg, a member of the firm's Commercial Litigation Department, was quoted in The San Diego Union-Tribune's article, "FTC antitrust case against Qualcomm puts business model under microscope."

Lawyers Wait to See How DOJ Merger Review Overhaul Plays Out

September 27, 2018

David Reichenberg, a member in the firm's Antitrust Group, was quoted in Global Competition Review's article, "Lawyers wait to see how DOJ merger review overhaul plays out."

Impact Of AmEx Decision On Tech Cos. Up For Debate

June 25, 2018

David Reichenberg, a member in the firm's Antitrust Practice, was quoted in Law360's article, "Impact Of AmEx Decision On Tech Cos. Up For Debate."

Supreme Court Says Foreign Gov't Submissions Not Binding

June 14, 2018

David Reichenberg, a member in the firm's Antitrust Practice, was quoted in Law360's "Supreme Court Says Foreign Gov't Submissions Not Binding."

Antitrust Litigator Joins Commercial Litigation Department

April 05, 2018

David Reichenberg has represented U.S. tech leaders, including Google, Netflix, and Twitter

Publications

Deterring Gaming of the Generic Drug Approval Process by the Use of Citizen Petitions [Intellectual Property Alert]

October 15, 2018

Marilyn Neiman, David Reichenberg, and Martin B. Pavane discuss the FDA's updated guidance on citizen petitions that now includes factors that the FDA will consider in determining whether a citizen petition is submitted for the primary purpose of delaying approval of a generic drug.

Events & Seminars

Past Events

Antitrust Trials: Tips and Tricks From Outside Counsel

February 07, 2019 - TELECONFERENCE

Health Law 2019

December 05, 2018 - Philadelphia, PA

ABA's 66th Antitrust Law Spring Meeting

April 11, 2018 - Washington, DC

Education

  • Fordham University School of Law, J.D., 2006
  • Cornell University, B.S., with honors, 2003

Awards & Honors

New York Super Lawyers Rising Stars, 2015-2017

  • New York
  • U.S. District Court -- Eastern District of New York
  • U.S. District Court -- Southern District of New York
  • U.S. District Court -- Western District of New York
  • U.S. Court of Appeals for the Second Circuit
  • U.S. Court of Appeals for the Ninth Circuit